Cargando…

Cystic Fibrosis: Systems Biology Analysis from Homozygous p.Phe508del Variant Patients' Samples Reveals Perturbations in Tissue-Specific Pathways

Cystic fibrosis (CF) is an autosomal recessive disorder, caused by diverse genetic variants for the CF transmembrane conductance regulator (CFTR) protein. Among these, p.Phe508del is the most prevalent variant. The effects of this variant on the physiology of each tissue remains unknown. This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Faria Poloni, Joice, Rispoli, Thaiane, Rossetti, Maria Lucia, Trindade, Cristiano, Vargas, José Eduardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660202/ https://www.ncbi.nlm.nih.gov/pubmed/34901273 http://dx.doi.org/10.1155/2021/5262000

Ejemplares similares

Assessment of p.Phe508del-CFTR functional restoration in pediatric primary cystic fibrosis airway epithelial cells
por: Sutanto, Erika N., et al.
Publicado: (2018)

Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis
por: Beumer, Wouter, et al.
Publicado: (2019)

Non‐pulmonary CFTR‐related symptom improvement with ivacaftor in p.Phe508del/p.Arg117His (7T) cystic fibrosis
por: Kuek, Stephanie L., et al.
Publicado: (2022)

Apparent Homozygosity of p.Phe508del in CFTR due to a Large Gene Deletion of Exons 4–11
por: Neocleous, Vassos, et al.
Publicado: (2014)

The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells
por: Stanke, Frauke, et al.
Publicado: (2014)

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET
por: Vugts, Danielle J., et al.
Publicado: (2016)

Functional analysis of the p.[Arg74Trp;Val201Met;Asp1270Asn]/p.Phe508del CFTR mutation genotype in human native colon
por: Schucht, Sylvia, et al.
Publicado: (2019)

GCK-MODY (MODY 2) Caused by a Novel p.Phe330Ser Mutation
por: Bonfig, Walter, et al.
Publicado: (2011)

The p.Phe174Ser mutation is associated with mild forms of Smith Lemli Opitz Syndrome
por: Tucci, Arianna, et al.
Publicado: (2016)

PTPN11 c.853T>C (p.Phe285Leu) mutation in Noonan syndrome with chylothorax
por: Watanabe, Daisuke, et al.
Publicado: (2022)

Late-onset fabry disease due to the p.Phe113Leu variant: the first italian cluster of five families
por: Cianci, Vittoria, et al.
Publicado: (2023)

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
por: Terlizzi, Vito, et al.
Publicado: (2021)

First report of the cystic fibrosis transmembrane conductance regulator mutation c.1521_1523delCTT (p. Phe508del) in two Qatari patients with cystic fibrosis
por: AbdulWahab, Atqah, et al.
Publicado: (2021)

CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftor
por: Raraigh, Karen S., et al.
Publicado: (2022)

Novel RHD allele with c.333C>G change predicted to encode p.Phe111Leu
por: Alluin, Gauthier, et al.
Publicado: (2022)

DeltaF508 CFTR Hetero- and Homozygous Paediatric Patients with Cystic Fibrosis Do Not Differ with Regard to Nutritional Status
por: Mędza, Aleksandra, et al.
Publicado: (2021)

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
por: Yaacoby-Bianu, Karin, et al.
Publicado: (2022)

A family with novel homozygous deletion mutation (c.1255delT; p.Phe419Serfs*12) in the glucokinase gene, which is a rare cause of permanent neonatal diabetes mellitus
por: Bolu, Semih, et al.
Publicado: (2020)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

Decoding F508del Misfolding in Cystic Fibrosis
por: Wang, Xiaodong Robert, et al.
Publicado: (2014)

A Pathogenic Variant p.Phe177Val in PSEN1 Causes Early-Onset Alzheimer’s Disease in a Chinese Family
por: Jiang, Bin, et al.
Publicado: (2020)

P079 Real-life data on the efficacy and safety of tezacaftor/ivacaftor in people living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation
por: Vincken, S., et al.
Publicado: (2022)

Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
por: Horn, Tabea, et al.
Publicado: (2020)

Evaluation of the Complex p.[Leu467Phe;Phe508del] CFTR Allele in the Intestinal Organoids Model: Implications for Therapy
por: Kondratyeva, Elena, et al.
Publicado: (2022)

Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR
por: Matos, Ana M., et al.
Publicado: (2018)

CFTR-F508 pigs provide new clues to cystic fibrosis
Publicado: (2011)

Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi(®)) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
por: Favia, Maria, et al.
Publicado: (2020)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

The Arrhythmogenic Calmodulin p.Phe142Leu Mutation Impairs C-domain Ca(2+) Binding but Not Calmodulin-dependent Inhibition of the Cardiac Ryanodine Receptor
por: Søndergaard, Mads Toft, et al.
Publicado: (2017)

A Japanese boy with fructose-1,6-bisphosphatase deficiency who had a novel FBP1 mutation (p.Phe90Val)
por: Nagahara, Keiko, et al.
Publicado: (2017)

Fumarate hydratase c.914T > C (p.Phe305Ser) is a pathogenic variant associated with hereditary leiomyomatosis and renal cell cancer syndrome
por: Breen, Kelsey E., et al.
Publicado: (2020)

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
por: Pohl, Kerstin, et al.
Publicado: (2018)

Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis
por: Esposito, Speranza, et al.
Publicado: (2016)

ΔF508 CFTR interactome remodeling promotes rescue of Cystic Fibrosis
por: Pankow, Sandra, et al.
Publicado: (2015)

P.F508del editing in cells from cystic fibrosis patients
por: Smirnikhina, Svetlana A., et al.
Publicado: (2020)

An Asymptomatic, Ectopic Mass as a Presentation of Adrenocortical Carcinoma Due to a Novel Germline TP53 p.Phe338Leu Tetramerisation Domain Variant
por: Walenciak, Justyna, et al.
Publicado: (2023)

Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice
por: Legssyer, Rachida, et al.
Publicado: (2006)

Screening for F508del as a first step in the molecular diagnosis of cystic fibrosis,
por: Marson, Fernando Augusto de Lima, et al.
Publicado: (2013)

Impact of MIF Gene Promoter Polymorphism on F508del Cystic Fibrosis Patients
por: Melotti, Paola, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1crablpphesdflfp0rihcqs0o2